---
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285398940.md"
description: "InflaRx shares are trading higher after the company announced that it intends to develop izicopan, an oral C5a receptor inhibitor with potential best-in-class properties, in AAV, a life-threatening kidney disorder."
datetime: "2026-05-06T14:40:31.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285398940.md)
  - [en](https://longbridge.com/en/news/285398940.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285398940.md)
---

# 

InflaRx shares are trading higher after the company announced that it intends to develop izicopan, an oral C5a receptor inhibitor with potential best-in-class properties, in AAV, a life-threatening kidney disorder.

### Related Stocks

- [IFRX.US](https://longbridge.com/en/quote/IFRX.US.md)

## Related News & Research

- [01:00 ETNational Kidney Foundation Innovation Fund Invests in Biohope to Advance Personalized Medicine in Kidney Transplantation](https://longbridge.com/en/news/286359416.md)
- [InflaRx Announces Advancement of Izicopan in ANCA-Associated Vasculitis and Select Renal Diseases | IFRX Stock News](https://longbridge.com/en/news/285377138.md)
- [AstraZeneca wins US approval for first‑in‑class Baxfendy in hypertension](https://longbridge.com/en/news/286904730.md)
- [Onco-Innovations Strengthens Quality Testing for Lead PNKP Inhibitor Drug Candidate | ONNVF Stock News](https://longbridge.com/en/news/286620198.md)
- [CervoMed Reports First Quarter 2026 Financial Results and Provides Corporate Updates | CRVO Stock News](https://longbridge.com/en/news/286766468.md)